Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion

DRUG2 trials

Sponsors

Lymphoma Academic Research Organisation, Centre Hospitalier Universitaire De Saint Etienne

Conditions

hematologyrelapsed or refractory patients with aggressive large B-cell lymphoma at high risk of relapse

Phase 2

CARMOD - Golcadomide (BMS-986369) post-CAR T-cell in R/R Aggressive large B-cell lymphoma patients with high risk of relapse

RecruitingCTIS2023-506705-20-00

Lymphoma Academic Research Organisationrelapsed or refractory patients with aggressive large B-cell lymphoma at high risk of relapse

Start: 2024-06-14Target: 61Updated: 2024-05-28

Phase 4

Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector Cell-Associated Neurotoxicity Syndrome : the VESICANS study

RecruitingCTIS2024-515328-35-00

Centre Hospitalier Universitaire De Saint Etiennehematology

Start: 2025-07-02Target: 60Updated: 2025-04-17